BackgroundA new syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) has emerged as a rare side-effect of vaccination against COVID-19. Cerebral venous thrombosis is the most common manifestation of this syndrome but, to our knowledge, has not previously been described in detail. We aimed to document the features of post-vaccination cerebral venous thrombosis with and without… Continue reading Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study
Tag: Thrombosis
VTE Prophylaxis in Critically Ill AdultsA Systematic Review and Network Meta-analysis
BackgroundCritically ill adults are at increased risk of VTE, including DVT, and pulmonary embolism. Various agents exist for venous thromboprophylaxis in this population. Research QuestionWhat is the comparative efficacy and safety of prophylaxis agents for prevention of VTE in critically ill adults?Study Design and MethodsSystematic review and network meta-analysis of randomized clinical trials (RCTs) evaluating… Continue reading VTE Prophylaxis in Critically Ill AdultsA Systematic Review and Network Meta-analysis
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England
BackgroundThromboses in unusual locations after the Coronavirus Disease 2019 (COVID-19) vaccine ChAdOx1-S have been reported, although their frequency with vaccines of different types is uncertain at a population level. The aim of this study was to estimate the population-level risks of hospitalised thrombocytopenia and major arterial and venous thromboses after COVID-19 vaccination. Methods and findingsIn… Continue reading Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England
SARS-CoV-2 vaccines: Lights and shadows
Highglights• So far, vaccines to prevent SARS-CoV-2 infection appear as promising approach for curbing the pandemic. • Vaccines for SARS-CoV-2 are being developed using several different platforms. • Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines on the basis of rare adverse reactions, particularly thromboembolic. • The applicability to the real life… Continue reading SARS-CoV-2 vaccines: Lights and shadows
Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19
COVID-19 vaccine is the hope for containment of disease outbreak. The post vaccination adverse effect is an important consideration. The clot after vaccination is an emerging important clinical problem in some vaccine recipients.1 The cause of post vaccination blood clot is not known. It is proposed that the problem might be due to immunopathological process.2… Continue reading Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19
Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases
There is accumulating evidence that SARS-CoV-2 vaccinations can be complicated by venous sinus thrombosis (VST). This review aimed at summarising and discussing previous and recent advances regarding the diagnosis, pathogenesis, treatment, and outcome of post-SARS-CoV-2 vaccination VST. At least 308 patients with post-SARS-CoV-2 vaccination VST have been reported as per the end of July 2021.… Continue reading Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge; the role of extended thromboprophylaxis in this population is unknown. MethodsIn this open-label, multicentre, randomised trial conducted at 14 centres in Brazil, patients hospitalised with COVID-19 at increased risk for venous thromboembolism (International Medical Prevention Registry on Venous Thromboembolism [IMPROVE] venous thromboembolism [VTE]… Continue reading Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
Long-Term Risk for Major #Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous #Thromboembolism
The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain. Purpose:To determine the incidence of major bleeding during extended anticoagulation of up to 5 years among patients with a first unprovoked VTE, overall, and in clinically important… Continue reading Long-Term Risk for Major #Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous #Thromboembolism
#Cerebral venous #thrombosis after vaccination against #COVID-19 in the UK: a multicentre cohort study
A new syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) has emerged as a rare side-effect of vaccination against COVID-19. Cerebral venous thrombosis is the most common manifestation of this syndrome but, to our knowledge, has not previously been described in detail. We aimed to document the features of post-vaccination cerebral venous thrombosis with and without… Continue reading #Cerebral venous #thrombosis after vaccination against #COVID-19 in the UK: a multicentre cohort study
2 Medical News 